Dr. Gregory Sorensen

Nuclear Medicine
Alzheimer's disease: Reason for hope
When President Reagan welcomed women's basketball coach Pat Summitt to the White House 25 years ago, no one knew that Alzheimer's would someday become a thread connecting them. Fortunately, imaging now offers more certainty for those who may unknowingly have the disease, according to Siemens Healthcare CEO Dr. Gregory Sorensen.
August 5, 2012
2012 08 03 13 29 17 498 Sorensen Gregory 70
Page 1 of 1
Top Stories
Snmmi 1 7s Z4 A1v Jrn Thumbnail
Molecular Imaging
SNMMI: New molecular imaging agent shows promise for detecting HCC
A new molecular imaging agent has shown high sensitivity and specificity in detecting hepatocellular carcinoma (HCC).
Women Cancer Patient 400
Molecular Imaging
SNMMI: PET imaging improves OMD detection in breast cancer patients
F18 Fds Pet In Human Snmmi 2025 Johns Hopkins Research Thumbnail
Molecular Imaging
SNMMI: F-18 FDS PET distinguishes molds in invasive fungal infections
Wang Ioy Image Thumbnail
Molecular Imaging
SNMMI: New immuno-PET tracer awarded Image of the Year
Join Us June 26 at 12 Noon ET for a FREE webinar!
Sponsor Content
Join Us June 26 at 12 Noon ET for a FREE webinar!
More in Home
SNMMI: New molecular imaging agent shows promise for detecting HCC
By Kate Madden Yee
A new molecular imaging agent has shown high sensitivity and specificity in detecting hepatocellular carcinoma (HCC).
June 23, 2025
Snmmi 1 7s Z4 A1v Jrn Thumbnail
SNMMI: PET imaging improves OMD detection in breast cancer patients
By Amerigo Allegretto
PET imaging improves oligometastatic breast cancer detection over conventional imaging.
June 23, 2025
Women Cancer Patient 400
SNMMI: F-18 FDS PET distinguishes molds in invasive fungal infections
By Liz Carey
Novel PET radiotracer shows promise for molecular imaging infection and inflammation.
June 23, 2025
F18 Fds Pet In Human Snmmi 2025 Johns Hopkins Research Thumbnail
SNMMI: New immuno-PET tracer awarded Image of the Year
By Will Morton
A new immuno-PET tracer is superior to conventional F-18 FDG in patients with head and neck cancer.
June 23, 2025
Wang Ioy Image Thumbnail
SNMMI: PET/MRI helps manage patients with chronic spinal pain
By Will Morton
F-18 FDG-PET/MRI scans can detect previously unidentified locations of chronic spinal pain.
June 23, 2025
Coronal fused FDG-PET/MRI image of a patient with right upper back pain demonstrates asymetric uptake in the right trapezius muscle without abnormality on MRI to suggest edema or denervation injury. Trigger point lidocaine injection of the area based on PET/MRI findings resulted in complete relief of symptoms (pain score reduced to 0 from a baseline of 6).
SNMMI: Dual-targeting radioligand therapy safe for several cancers
By Will Morton
A new "dual-targeting" radioligand therapy has been shown to be safe and effective in humans.
June 22, 2025
Fapi Rgd Thumbnail
Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines
By Will Morton
A video interview with Phillip Kuo, MD, PhD, on Alzheimer's disease imaging.
June 22, 2025
Screenshot (2455)
SNMMI: Dual PET/MRI technique could help manage primary aldosteronism
By Will Morton
Using two imaging agents with PET/MRI could help manage patients with primary aldosteronism.
June 22, 2025
Pa eymt6 J Xb Ss Thumbnail
SNMMI: Retreatment with Lu-177 PSMA-617 shows promise in mCRPC patients
By Will Morton
Retreatment with Lu-177 PSMA-617 is emerging as a potential approach in men with prostate cancer.
June 21, 2025
Gokce Bilgin, MD, presented results of a Pluvicto study June 21 at SNMMI 2025 in New Orleans.
SNMMI: New PET tracers developed for imaging brain disorders
By Will Morton
Two newly developed PET imaging agents are effective for identifying a highly expressed receptor in neurological and psychiatric conditions.
June 21, 2025
New H3 Tracers Thumbnail
SNMMI: SPECT/CT valuable after Lu-177 therapy
By Will Morton
Post-therapy SPECT/CT imaging can optimize treatment outcomes and protected patients undergoing radiopharmaceutical therapy.
June 21, 2025
Top image displays a patient assessed for acute renal failure following third Lutathera administration where 3D dosimetry showed an average-per-administration kidney absorbed dose of 5 Gray, with total course of therapy being well under toxicity limits. Bottom image displays a patient’s absorbed dose to the colon after his first dose of Pluvicto where 3D dosimetry was used to confirm transient bowel obstruction leading to treatment management.
DL model improves detection of breast arterial calcifications
By Amerigo Allegretto
Researchers have developed a deep-learning (DL) model that can find and characterize breast arterial calcifications on mammograms.
June 20, 2025
2025 06 20 Academicrad Bacs Deep Learning Thumbnail
Page 1 of 147
Next Page